Skip to main content
. 2018 Apr 26;62(5):e02419-17. doi: 10.1128/AAC.02419-17

FIG 5.

FIG 5

In vivo antileishmanial activity of benzoxaboroles upon oral and topical application. (A) Progression of the main lesion size (measured using digital calipers) per group as a function of time postinfection (mean ± SD, n = 6); (B) average number of amastigotes found per lesion, as analyzed by qPCR, and the average lesion size per group 3 days after the end of treatment (mean ± SD, n = 5). iv, intravenous.